Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEOPATTRA: NNC6019-0001 in ATTR-CM
NCT07207811Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2025
- Primary completion
- Jun 2029
- Countries
- 20
01
Overview
A Phase 3 trial of coramitug in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Novo Nordisk. Started Oct 2025; status: recruiting.
02
Drugs
coramitug
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT07207811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07207811.